Encorafenib (Braftovi) for the treatment of metastatic colorectal cancer (bowel cancer)

Introduction

Encorafenib (trade name: Braftovi) has been approved in Germany since June 2020 for the treatment of metastatic (bowel cancer) in adults when combined with the drug cetuximab. This combination is an option for treating metastatic in adults who have a mutated protein in the cancer tissue (BRAF V600E mutation) and have already received systemic treatment.

Colorectal cancer almost always develops from a particular kind of polyp in the intestine (bowel), known as an . These are non-cancerous (benign) growths in the mucous membrane of the bowel. Most adenomas remain small and are not dangerous. Only few of them change and become cancerous (malignant). Although the small intestine is quite a lot longer than the large intestine, bowel cancer almost always develops in the large intestine (colon) or the . These types of cancer are also called colorectal carcinoma.

Bowel cancer often doesn’t cause any symptoms at first, so it may remain unnoticed for a while. In advanced metastatic bowel cancer, the tumor has spread to other parts of the body and complete recovery is generally no longer possible.

Encorafenib is supposed to inhibit the mutated protein in order to slow down the growth of the cancer.

Application

Encorafenib is available as capsules, in two doses: 50 or 75 mg. The total dose is 300 mg once a day.

Encorafenib is used in combination with cetuximab.

Other treatments

For people who have had previous treatment for metastatic with the BRAF V600E mutation, a combination of cancer drugs are adjusted individually by their doctor.

Assessment

In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether encorafenib has any advantages or disadvantages in the treatment of metastatic in people with the BRAF V600E mutation when compared to an individual treatment adjusted by the patient's doctor.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benfit of encorafenib (Braftovi).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany).  Encorafenib (colorectal cancer) – Benefit assessment according to § 35a SGB V. Dossier assessment; Commission A20-56. September 29, 2020. (IQWiG reports; Volume 976).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on October 22, 2020
Next planned update: 2023

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.